Denmark, Italy, Austria and Iceland suspend use of Astra-Zeneca vaccines due to concerns over blood clots.
It’s the latest setback for AstraZeneca’s European rollout; delayed deliveries fueled a dispute between the EU and the U.K. and there were questions over its efficacy for people over 65.
AstraZeneca said the safety of its vaccine was demonstrated in clinical trials. An analysis of more than 10 million records has shown no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any age group, gender, batch or country using the shot, the company said in a statement.
